[Picotamide: use in chronic obliterative arteriopathies of the lower limbs].
In the present study the authors evaluated treatment efficiency and patient compliance of medium-term therapy with Picotamide, given in doses of 900 mg/die for the first 15 days, and 600 mg/die up to the completion of a three-month period, to 50 patients affected by vaso-occlusive arterial disease of the lower limbs. At follow-up visits the following controls have been carried out: CW Doppler sonography of the lower limbs, Maximum Walking Distance (M.W.D.), Red blood cell count, White blood cell count, Platelet count, Haemoglobin and Fibrinogen levels. At the end of the three-month therapy period the Ankle-Arm parameters remained unchanged.
Tazza
G
G
Istituto di Clinica Medica, Università degli Studi di Perugia.
Tazza
R
R
Valentini
M
M
Leoni
G
G
Avenia
N
N
Ragusa
M
M
D000368:Aged; D001157:Arterial Occlusive Diseases / Q000175:diagnosis / Q000188:drug therapy*; D005260:Female; D006801:Humans; D007866:Leg / Q000098:blood supply*; D008297:Male; D008875:Middle Aged; D010795:Phthalic Acids / Q000008:administration & dosage / Q000627:therapeutic use*; D013997:Time Factors
D010795:Phthalic Acids; C011581:picotamide
Picotamide: utilizzo nelle arteriopatie obliteranti croniche degli arti inferiori.